U.S. Markets close in 5 hrs 37 mins

Marker Therapeutics, Inc. (MRKR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.6500+0.0600 (+3.77%)
As of 10:21AM EST. Market open.

Marker Therapeutics, Inc.

Phoenix Tower
Suite 2240 3200 Southwest Freeway
Houston, TX 77027
United States
713 400 6400

Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter L. Hoang MBAPres, CEO & Director451.67kN/A1972
Mr. Anthony H. KimChief Financial Officer431.52kN/A1976
Dr. Juan F. Vera M.D.Chief Devel. Officer & DirectorN/AN/A1980
Dr. Mythili Koneru M.D., Ph.D.Chief Medical Officer405.11kN/A1978
Mr. Michael J. LoiaconoChief Accounting Officer, Treasurer & Sec.N/AN/A1966
Ms. Elizabeth DonnellyDirector of Admin.N/AN/AN/A
Ms. Shelia SterrDirector of HR & Fin.N/AN/AN/A
Dr. Robert Z. Florkiewicz Sr.Sr. Director of Molecular Biology & VirologyN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Corporate Governance

Marker Therapeutics, Inc.’s ISS Governance QualityScore as of November 2, 2019 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.